Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous …

JR Johnson, P Bross, M Cohen, M Rothmann… - Clinical Cancer …, 2003 - AACR
Purpose: The purpose is to describe the Food and Drug Administration (FDA) review and
approval of imatinib (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of …
被引用次数：132 相关文章

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia …

JR Johnson, P Bross, M Cohen… - … : an official journal …, 2003 - pubmed.ncbi.nlm.nih.gov
Purpose The purpose is to describe the Food and Drug Administration (FDA) review and
approval of imatinib (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of …

[引用][C] Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous …

JR JOHNSON, P BROSS, M COHEN… - Clinical cancer …, 2003 - pascal-francis.inist.fr
Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly
diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic …

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia …

JR Johnson, P Bross, M Cohen… - … Cancer Research: an …, 2003 - europepmc.org
Purpose The purpose is to describe the Food and Drug Administration (FDA) review and
approval of imatinib (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of …